{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:16:29Z","timestamp":1778264189358,"version":"3.51.4"},"reference-count":41,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Richter transformation is a rare phenomenon characterized by the transformation of cell chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma variant. The early identification of CLLs with a high risk of RT is fundamental. In this field, 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography\/computed tomography (2-[18F]FDG PET\/CT) has been shown to be a non-invasive and promising tool, but apparently, unclear data seem to be present in the literature. This systematic review and bivariate meta-analysis aimed to investigate the diagnostic performance of 2-[18F]FDG PET\/CT and its parameters in predicting RT. Between 2006 and 2024, 15 studies were published on this topic, including 1593 CLL patients. Among semiquantitative variables, SUVmax was the most investigated, and the best threshold derived for detecting RT was five. With this cut-off value, a pooled sensitivity of 86.8% (95% CI: 78.5\u201393.3), a pooled specificity of 48.1% (95% CI: 27\u201369.9), a pooled negative predictive value of 90.5% (95% CI: 88.4\u201392.4), a pooled negative likelihood ratio of 0.35 (95% CI: 0.17\u20130.70), a pooled positive likelihood ratio of 1.8 (95% CI: 1.3\u20132.4), and a pooled diagnostic odds ratio of 6.7 (3.5\u201312.5) were obtained. With a higher cut-off (SUVmax = 10), the specificity increased while the sensitivity reduced. The other metabolic features, like metabolic tumor volume, total lesion glycolysis, and radiomic features, were only marginally investigated with controversial evidence.<\/jats:p>","DOI":"10.3390\/cancers16091778","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T13:27:00Z","timestamp":1715002020000},"page":"1778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Diagnostic Performance of 2-[18F]FDG PET\/CT in Identifying Richter Transformation in Chronic Lymphocytic Leukemia: An Updated Systematic Review and Bivariate Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[{"name":"Nuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5438-8230","authenticated-orcid":false,"given":"Alessio","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9350-1239","authenticated-orcid":false,"given":"Manuela","family":"Racca","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Muoio","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6501 Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-780X","authenticated-orcid":false,"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland"},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), 6900 Lugano, Switzerland"},{"name":"Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","article-title":"The pathogenesis of chronic lymphocytic leukemia","volume":"9","author":"Zhang","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2016.08.021","article-title":"Richter\u2019s transformation in the era of kinase inhibitor therapy: A review","volume":"17","author":"Ayers","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.beha.2016.08.006","article-title":"Richter\u2019s syndrome: Novel and promising therapeutic alternatives","volume":"29","author":"Rossi","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-017-3149-9","article-title":"Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies","volume":"97","author":"Khan","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11864-017-0512-y","article-title":"Treatment of Richter\u2019s Syndrome","volume":"18","author":"Condoluci","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Briski, R., and Taylor, J. (2023). Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era. Cancers, 15.","DOI":"10.3390\/cancers15061857"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_10","first-page":"e968","article-title":"Richter Transformation of Chronic Lymphocytic Leukemia: A Review of Fluorodeoxyglucose Positron Emission Tomography\u2013Computed Tomography and Molecular Diagnostics","volume":"9","author":"Shaikh","year":"2017","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cpet.2019.03.007","article-title":"PET\/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation","volume":"14","author":"Rhodes","year":"2019","journal-title":"PET Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40336-016-0219-2","article-title":"Systematic reviews and meta-analyses of diagnostic studies: A practical guideline","volume":"5","author":"Sadeghi","year":"2017","journal-title":"Clin. Transl. Imaging"},{"key":"ref_14","first-page":"1267","article-title":"Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of Fluorine-18 Fluoro-Deoxyglucose Positron Emission Tomography Scan in the Evaluation and Follow-Up of Patients with Low-Grade Lymphomas","volume":"107","author":"Karam","year":"2006","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12149-012-0639-7","article-title":"Role of 18F-FDG PET-CT for evaluating the response to reduced intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: Preliminary results in nine patients","volume":"26","author":"Taralli","year":"2012","journal-title":"Ann. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/10428194.2013.802313","article-title":"2-[18 F]fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Flodr","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3109\/10428194.2013.869801","article-title":"Use of positron emission tomography-computerized tomography (PET-CT) in the management of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL)","volume":"55","author":"Conte","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET findings, histological features, clinical characteristics and survival in 332 patients with chronic lymphocytic leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter\u2019s Syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3324\/haematol.2018.207068","article-title":"Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato","year":"2019","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients with Richter Syndrome","volume":"45","author":"Pointoizeau","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_24","first-page":"240564","article-title":"The role of 18F-FDG-PET in detecting Richter transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Porrazzo, M., Nicolai, E., Riminucci, M., Vitale, C., Coscia, M., De Paoli, L., Rago, A., Buscicchio, G., Maestrini, G., and Ligia, S. (2020). Prognostic Significance of PET\/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12071773"},{"key":"ref_26","first-page":"30670","article-title":"2-[18F]-FDG PET\/CT role in detecting Richter\u2019s transformation of Chronic Lymphocytic Leukemia and predicting overall survival","volume":"S2152\u2013S2650","author":"Albano","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.clml.2021.04.003","article-title":"The Pattern of Use of PET\/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia","volume":"21","author":"Hod","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Albano, D., Calabr\u00f2, A., Dondi, F., and Bertagna, F. (2024). 2-[18F]-FDG PET\/CT Semi-quantitative and Radiomics Predictive Parameters of Richter\u2019s Transformation in CLL Patients. Medicina, 60.","DOI":"10.3390\/medicina60020203"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bertagna, F., Giubbini, R., and Albano, D. (2020). Evidence-Based PET for Haematological Tumours, Springer.","DOI":"10.1007\/978-3-030-47701-1_9"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/joim.12813","article-title":"FDG-PET\/CT in the management of lymphomas: Current status and future directions","volume":"284","author":"Villa","year":"2018","journal-title":"J. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17474086.2020.1690987","article-title":"Histological transformation in malignant lymphoma: A possible role of PET\/CT and circulating tumor DNA as non-invasive diagnostic tools","volume":"13","author":"Ohmoto","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","article-title":"Metabolic tumour volume metrics in lymphoma","volume":"48","author":"Kostakoglu","year":"2018","journal-title":"Semin. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12149-020-01521-3","article-title":"The contribution of metabolic parameters of FDG PET\/CT prior and during therapy of adult patients with lymphomas","volume":"34","author":"Hatzimichael","year":"2020","journal-title":"Ann. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","article-title":"Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: A systematic review","volume":"48","author":"Frood","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11307-022-01703-7","article-title":"Role of Radiomics-Based Baseline PET\/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment","volume":"24","author":"Jiang","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymeth.2020.06.020","article-title":"Functional imaging using radiomic features in assessment of lymphoma","volume":"188","author":"Mayerhoefer","year":"2021","journal-title":"Methods"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s00330-020-07390-8","article-title":"Are lesion features reproducible between 18F-FDG PET\/CT images when acquired on analog or digital PET\/CT scanners?","volume":"31","author":"Constantino","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1007\/s00259-019-04300-z","article-title":"Digital PET\/CT: A new intriguing chance for clinical nuclear medicine and personalized molecular imaging","volume":"46","author":"Schillaci","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Honor\u00e9 d\u2019Este, S., Andersen, F.L., Andersen, J.B., Jakobsen, A.L., Sanchez Saxtoft, E., Schulze, C., Hansen, N.L., Andersen, K.F., Reichkendler, M.H., and H\u00f8jgaard, L. (2023). Potential Clinical Impact of LAFOV PET\/CT: A Systematic Evaluation of Image Quality and Lesion Detection. Diagnostics, 13.","DOI":"10.3390\/diagnostics13213295"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/RLI.0000000000000469","article-title":"[68Ga]Ga-Pentixafor PET\/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results","volume":"53","author":"Mayerhoefer","year":"2018","journal-title":"Investig. Radiol."},{"key":"ref_41","first-page":"1687","article-title":"Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J. Nucl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:39:50Z","timestamp":1760107190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16091778"],"URL":"https:\/\/doi.org\/10.3390\/cancers16091778","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,5]]}}}